Efficacy and safety of flumatinib in the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase: A real-world single-center retrospective study, with a focus on premature drug discontinuation

IF 2.1 4区 医学 Q3 HEMATOLOGY
Mingshan Sun, Shijie Li, Zhenyi Liu, Sai Ma, Xiaohan Liu, Qing Meng, Yueyue Zheng, Chunyan Chen
{"title":"Efficacy and safety of flumatinib in the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase: A real-world single-center retrospective study, with a focus on premature drug discontinuation","authors":"Mingshan Sun,&nbsp;Shijie Li,&nbsp;Zhenyi Liu,&nbsp;Sai Ma,&nbsp;Xiaohan Liu,&nbsp;Qing Meng,&nbsp;Yueyue Zheng,&nbsp;Chunyan Chen","doi":"10.1016/j.leukres.2024.107507","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>To assess the real-world efficacy and safety of flumatinib as first-line and post-line treatments for chronic myeloid leukemia in the chronic phase (CML-CP).</p></div><div><h3>Results</h3><p>Among 141 patients receiving flumatinib as first-line and post-line treatment, the 12-month major molecular response (MMR) rates were 69.4% and 67.6%, respectively. The median time to response was 6 and 10.5 months, respectively. In post-line treatment, the early molecular response (EMR) of flumatinib as second-line is significantly superior to that of third-line treatment (3-month EMR rate: 79.2% vs. 39.3%, P&lt;0.001; 3-month MMR rate: 45.8% vs. 21.4%, P=0.033). Contrastively, patients who switched to flumatinib due to intolerance had significantly higher MMR rates at 3, 6, and 12 months compared to patients who switched due to inadequate response (60.6% vs. 24.2%, P=0.003; 66.7% vs. 36.0%, P=0.027; 84.2% vs. 50.0%, P=0.038). Premature drug discontinuation was observed in 28.4% of the patients. Grades 3–4 hematologic adverse events (AEs) were identified as independent risk factors for premature drug discontinuation. Patients who discontinued treatment and those who previously received only imatinib therapy had a poorer molecular response and failure-free survival.</p></div><div><h3>Conclusions</h3><p>Flumatinib demonstrates favorable efficacy and safety. Treatment discontinuation can result in a poorer molecular response and long-term prognosis.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"142 ","pages":"Article 107507"},"PeriodicalIF":2.1000,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0145212624000730","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

To assess the real-world efficacy and safety of flumatinib as first-line and post-line treatments for chronic myeloid leukemia in the chronic phase (CML-CP).

Results

Among 141 patients receiving flumatinib as first-line and post-line treatment, the 12-month major molecular response (MMR) rates were 69.4% and 67.6%, respectively. The median time to response was 6 and 10.5 months, respectively. In post-line treatment, the early molecular response (EMR) of flumatinib as second-line is significantly superior to that of third-line treatment (3-month EMR rate: 79.2% vs. 39.3%, P<0.001; 3-month MMR rate: 45.8% vs. 21.4%, P=0.033). Contrastively, patients who switched to flumatinib due to intolerance had significantly higher MMR rates at 3, 6, and 12 months compared to patients who switched due to inadequate response (60.6% vs. 24.2%, P=0.003; 66.7% vs. 36.0%, P=0.027; 84.2% vs. 50.0%, P=0.038). Premature drug discontinuation was observed in 28.4% of the patients. Grades 3–4 hematologic adverse events (AEs) were identified as independent risk factors for premature drug discontinuation. Patients who discontinued treatment and those who previously received only imatinib therapy had a poorer molecular response and failure-free survival.

Conclusions

Flumatinib demonstrates favorable efficacy and safety. Treatment discontinuation can result in a poorer molecular response and long-term prognosis.

氟马替尼治疗新诊断的慢性髓性白血病慢性期的疗效和安全性:以过早停药为重点的真实世界单中心回顾性研究
目的 评估氟马替尼作为慢性粒细胞白血病(CML-CP)一线和线后治疗的实际疗效和安全性。结果 在141名接受氟马替尼一线和线后治疗的患者中,12个月的主要分子反应(MMR)率分别为69.4%和67.6%。中位应答时间分别为6个月和10.5个月。在二线治疗后,氟马替尼的早期分子反应(EMR)明显优于三线治疗(3个月EMR率:79.2%对39.5%):79.2% vs. 39.3%,P<0.001;3个月MMR率:45.8% vs. 21.4%,P<0.001:45.8%对21.4%,P=0.033)。相反,因不耐受而改用氟马替尼的患者与因反应不足而改用氟马替尼的患者相比,3、6和12个月的MMR率明显更高(60.6% vs. 24.2%,P=0.003;66.7% vs. 36.0%,P=0.027;84.2% vs. 50.0%,P=0.038)。28.4%的患者出现过早停药。3-4级血液学不良事件(AEs)被认为是导致过早停药的独立风险因素。中止治疗的患者和之前仅接受伊马替尼治疗的患者的分子反应和无失败生存期较差。结论 氟马替尼具有良好的疗效和安全性,但中断治疗会导致较差的分子反应和长期预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Leukemia research
Leukemia research 医学-血液学
CiteScore
4.00
自引率
3.70%
发文量
259
审稿时长
1 months
期刊介绍: Leukemia Research an international journal which brings comprehensive and current information to all health care professionals involved in basic and applied clinical research in hematological malignancies. The editors encourage the submission of articles relevant to hematological malignancies. The Journal scope includes reporting studies of cellular and molecular biology, genetics, immunology, epidemiology, clinical evaluation, and therapy of these diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信